Vertex drug challenged by low refill rates; the FDA has issued only 4 warning or untitled letters this year; Horizon settles PBM-rebate suit
Some U.S. hospitals still haven't received Valeant discounts; U.N. General Assembly will discuss antibiotic resistance; AstraZeneca diabetes drugs lowered blood sugar in study
The OPDP sent its second untitled letter this week, this time to Durect and Pain Therapeutics over the presentation of Remoxy ER.
Grassley blasts Mylan over EpiPen price increases; Portola Pharmaceuticals receives CRL letter for reversal agent; the FDA approves Pfizer's opioid
OncoGenex's prostate cancer drug fails in clinical trial; Aetna to exit exchanges in 11 states; pregnant women taking acetaminophen have higher risks for their children
IBM develops chip to detect early stages of cancer; Theranos plans to develop a "minilab;" Aetna and Humana to sell $117 million in assets
Pfizer to disclose addiction risk in promo materials for opioids; Medivation considers an acquisition; Almirall expresses interest in buying Valeant drugs
The drugmaker launched a three-part video series that uses humor to address prescription drug abuse.
Purdue Pharma launched a new resource around the abuse-deterrent properties of some of its painkillers.
Court blocks generic competition for Opana ER until 2023; lawmakers question Valeant drug price hikes; Roche's immuno-oncology drug meets primary endpoint in mid-stage trial
Study shows Merck's Januvia does not increase heart risks; a former Genentech exec launches a behavioral health business; lawmakers want black-box warnings on more opioids
Endo agrees to buy Par Pharmaceuticals for $8 billion; AstraZeneca deepens commitment to biologics; FDA cautions that certain diabetes drugs could lead to serious condition
Amarin sues FDA over off-label discussions; spike in HCV infections in US blamed on Endo opioid; Pfizer settles gambling, eating and sex addiction lawsuit
Takeda proposes $2.2-billion settlement to resolve Actos suits; Public Citizen says diabetes drugs are unlawfully promoted; PAIN study says 20% to 30% of opioid drugs are misused
A painkiller manufacturer said abuse-resistant formula lessens abuse, just as the FDA comes under pressure to finalize labeling guidance.
GlaxoSmithKline respiratory drug's safety profile will be evaluated by FDA advisory panel; Actavis axes 400 New York jobs; physician testifies that he falsified Diovan clinical trial data
The survey shows the use of stronger-than-morphine painkillers has jumped.
Bayer exec may be Sanofi's new CEO, GSK gets a new North American Pharma lead, and Pfizer sends painkiller ALO-02 to the FDA.
Hysingla ER is ready for the marketplace, just two months after FDA approval.
The CDC and March of Dimes Foundation are asking prescribers to discuss safer alternatives than opioid painkillers for women who may become pregnant.
Google teams up with PwC for DOD EHR project bid; FDA approves first weight-loss device since 2007; research says opioid abuse may be on the decline.
The bad news: heroin-related deaths inched upwards.
The Center for Drug Evaluation and Research's director says there is a need for new opioids and cuts off dosing comparisons between extended-release and immediate-release opioids.
The north-of-the-border solution comes amid climbing heroin abuse in the US.
The first approved hydrocodone formulated to discourage misuse raises a challenge to controversial Zohydro.
Drug makers favor big spending on speakers' events and doctor outreach.
The reveal comes days before hydrocodone products jump to a more restrictive access tier.
The reason: opioids.
The $300,000 grant will go towards an abuse-deterrent technology.
FDA feedback will influence a new clinical trial design, but the regulator's recent reaction was a bit of a surprise.
- Five things for pharma marketers to know: Thursday, October 20, 2016
- Five things for pharma marketers to know: Tuesday, October 18, 2016
- Five things for pharma marketers to know: Wednesday, October 19, 2016
- FCB Health's Rich Levy on HIV/AIDS Campaigns that Fight Stigma
- Five things for pharma marketers to know: Monday, October 24, 2016
- Merck educates doctors about biosimilars, long before it will sell one in the U.S.
- 4 trends with the potential to change behavior in the patient journey
- 2016 Pharma Report: All the data in one place
- What do physicians think about biosimilars?
- Novartis considers new sales model for experimental cancer therapy
- Sunovion hires former BI exec as VP of marketing
- If Roche's Ocrevus is approved, the already competitive MS market will gain another player
- Top 25 neurology products, based on 2016 sales forecasts
- New science drives biopharma interest in neurological conditions
- J&J exec calls California pricing measure 'misguided'